Along with NRAS, Crohn’s and Colitis UK and the Psoriasis Association, NASS want to understand your experiences of switching to a biosimilar medication.
NASS Position Statement on cannabis based products for medicinal use in axial spondyloarthritis (including ankylosing spondylitis) (AS)
What you can do if this affects you
On 7 January 2019 NHS England published its long-term plan for the NHS
NASS knows that not everyone in the UK gets the same standard of care for their axial SpA (AS) – that’s why we've launched our new campaign Every Patient, Every Time.
Meet the winners of our 2018 Patients' Choice Awards. This is what excellence looks like.